Written by Julia Rostova
The pharmaceutical landscape is currently dominated by a single, revolutionary class of drugs: GLP-1 receptor agonists. What began as a treatment for type 2 diabetes has evolved into a global phenomenon targeting obesity, a market analysts project will reach a staggering $100 billion by the end of the decade. For the past year, the narrative has been defined by a fierce duopoly between Novo Nordisk and Eli Lilly. However, the latest earnings reports, released over the past 48 hours, signal a critical inflection point in this battle: the transition from injectable pens to oral pills.
This shift in delivery mechanism is not merely a matter of patient convenience; it represents a massive expansion of the total addressable market. Millions of patients who were reluctant to self-administer injections are now entering the treatment funnel. As the battleground moves to oral formulations, the competitive dynamics are shifting rapidly, forcing investors to recalibrate their models and reassess valuations across the healthcare sector.
Novo Nordisk’s Stunning Reversal
Novo Nordisk (NVO) delivered a first-quarter earnings report on May 6 that completely shattered expectations, triggering a 6% surge in its stock price. The Danish pharmaceutical giant reported an adjusted operating profit of DKK 32.86 billion, with overall operating profit rising 65% year-over-year to 59.6 billion Danish crowns ($8.6 billion). Sales jumped 32% at constant exchange rates, driven by the explosive growth of its broader obesity care category, which rose 22%.
The undisputed star of the quarter was the newly launched Wegovy pill. Sales of the oral formulation reached 2.26 billion Danish crowns, nearly double the 1.16 billion forecast by analysts. CEO Mike Doustdar revealed that the Wegovy pill saw approximately 1.3 million prescriptions in the first quarter alone, pushing the total past 2 million since its January launch. Doustdar called the numbers “speaking for themselves” and highlighted that the product was well tolerated by patients.
Crucially, this success is not coming at the expense of existing products. Doustdar noted that the introduction of the pill is having a “synergetic effect” rather than cannibalizing sales of the injectable version, which still managed to grow 12% year-over-year to 18.2 billion crowns. The Wegovy brand now commands a dominant 65% of all new prescriptions in the U.S., a remarkable achievement that Doustdar accurately characterized as a “turnaround situation” for the company. Following a series of pipeline setbacks that pushed the stock to a 5-year low earlier this year, this earnings beat marks a definitive resurgence. The company also announced plans to launch the Wegovy pill outside the U.S. during the second half of 2026, pending regulatory approvals.
Thesis on NVO: BUY
Novo Nordisk is executing a masterclass in market expansion. The Wegovy pill is fundamentally altering the growth trajectory of the company, bringing in a massive cohort of patients averse to injections. Despite the recent 6% jump, the stock remains approximately 36% below its highs from the past year. With management raising full-year guidance and planning an international launch for the pill in the second half of 2026, NVO represents a compelling deep-value entry into the dominant player of a $100 billion market.
Eli Lilly’s Valuation Dilemma
While Novo Nordisk is capturing the momentum in oral formulations, Eli Lilly (LLY) remains a formidable adversary. The company recently reported a massive Q1 earnings beat, posting an EPS of $8.55 against a consensus estimate of $6.97—a $1.58 upside surprise. Revenue surged 56% year-over-year to $19.8 billion, driven by explosive growth in its injectable GLP-1 drugs: Mounjaro sales climbed 125% and Zepbound grew 80%.
However, Lilly’s foray into the oral market has been less spectacular. The company launched its own weight-loss pill, Foundayo, in early April. Early data indicates that Foundayo prescriptions are significantly lagging behind the Wegovy pill in their respective comparable launch periods, with reports suggesting Wegovy outpaced Foundayo 5-to-1 in the first week. Lilly CEO David Ricks acknowledged that the ramp-up for the completely new medicine will take “quarters, not days.”
The primary concern for investors is valuation. Eli Lilly’s stock has surged 13% in the past week alone, trading around $968. At approximately 26 times forward earnings, the market has priced in a flawless execution trajectory. Analysts at Barclays recently hiked their price target to an astonishing $1,400, reflecting the immense enthusiasm surrounding the stock. While the long-term thesis remains intact, the near-term risk-reward at these levels is less favorable than it was a week ago.
Thesis on LLY: HOLD
Eli Lilly’s execution in the injectable market is flawless, and its overall revenue growth is spectacular. However, the stock is currently priced for absolute perfection following a 13% weekly surge. The slow initial uptake of the Foundayo pill suggests that capturing market share in the oral segment will be a protracted battle against an entrenched competitor. Investors should maintain existing positions but exercise caution before deploying new capital at these elevated multiples.
The Regulatory Threat to Telehealth
The massive demand for GLP-1 medications has spawned a lucrative secondary market for compounded alternatives provided by telehealth companies. However, this business model is facing an existential threat. The U.S. Food and Drug Administration has proposed excluding the active ingredients for Novo Nordisk and Eli Lilly’s weight-loss drugs—semaglutide, tirzepatide, and liraglutide—from its 503B Bulk Drugs Substances List. If finalized, this ruling would force compounding pharmacies to cease production and distribution of these cheaper alternatives.
This regulatory crackdown is a massive tailwind for Novo Nordisk and Eli Lilly, as it eliminates low-cost competition and forces patients back to branded medications. Conversely, it poses a severe risk to telehealth providers heavily reliant on compounded GLP-1 revenue. Novo Nordisk has already filed patent infringement lawsuits against major telehealth providers, signaling an aggressive posture toward protecting its intellectual property.
Thesis on HIMS: SELL
Hims & Hers Health (HIMS) is highly vulnerable to the FDA’s proposed crackdown on compounded GLP-1s. While the company claims it does not expect an impact, the regulatory environment is turning hostile toward mass-market compounding of these drugs. With the company set to report earnings on May 11, the risk profile is heavily skewed to the downside. The core growth narrative is under direct regulatory threat, making the stock highly unattractive ahead of what could be a pivotal earnings call.
Strategic Implications
The obesity drug market is undergoing a rapid evolution. The introduction of oral GLP-1 formulations is expanding the total addressable market exponentially, bringing the projected $100 billion valuation into sharper focus. Novo Nordisk’s early dominance in the pill segment, combined with its depressed valuation relative to historical highs, makes it the most attractive pure-play investment in the space.
Simultaneously, the FDA’s move to protect branded intellectual property by restricting compounded alternatives ensures that the spoils of this market will be concentrated in the hands of the primary innovators. Investors must position their portfolios to capture the upside of this pharmaceutical supercycle while avoiding the regulatory risks associated with peripheral players. The GLP-1 pill wars have only just begun, and the early data decisively favors Novo Nordisk.
Equities Orbis | equitiesorbis.com
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
